

Resource Summary Report

Generated by NIF on Aug 11, 2026

TransCelerate BioPharma

RRID:SCR_003728

Type: Tool

Proper Citation

TransCelerate BioPharma (RRID:SCR_003728)

Resource Information

URL: <http://www.transceleratebiopharmainc.com/>

Proper Citation: TransCelerate BioPharma (RRID:SCR_003728)

Description: Non-profit research organization aiming to accelerate drug development by increasing the quality and efficiency of clinical studies through the development of shared tools, methods, and platforms. Consortium partnerships are limited to pharmaceutical and biotechnology companies with research & development operations, although there are collaborations with external organizations such the Clinical Data Interchange Standards Consortium (CDISC). Its current focus is to collaborate on: * Standardizing risk-based monitoring * Development of methods to qualify and train clinical trial sites * Development of a common investigator web portal * Development of clinical data standards on efficacy, and methods for comparator drug trials It currently has 5 projects: # Standardized Approach for High-Quality, Risk-Based Monitoring program aims to develop an industry-wide standard and approach for risk-based monitoring of clinical trials in order to enhance patient safety and ensure the quality of clinical trial data. # Shared Site Qualification and Training program aims to standardize GCP training and site qualification credentials in order to realize efficiencies and accelerate study start-up timelines. # Common Investigator Site Portal is a platform designed to streamline investigator and site access through harmonized delivery of content and services. # Data Standards project is a partnership with CDISC to develop industry-wide data standards in priority therapeutic areas to support the exchange and submission of clinical research and meta-data, improving patient safety and outcomes. # Comparator Drugs project aims to establish reliable, rapid sourcing of quality products for use in clinical trials through a comparator supply model enabling accelerated trial timelines and enhanced patient safety.

Abbreviations: TransCelerate

Synonyms: TransCelerate BioPharma Inc.

Resource Type: nonprofit organization

Keywords: drug, clinical trial, multipharma, data sharing, drug development, consortium, medicine, clinical, standard specification

Funding: Member companies financial contributions ;
Member companies in-kind contributions ;
GlaxoSmithKline

Resource Name: TransCelerate BioPharma

Resource ID: SCR_003728

Alternate IDs: nlx_157913

Record Creation Time: 20220129T080220+0000

Record Last Update: 20260808T185802+0000

Ratings and Alerts

No rating or validation information has been found for TransCelerate BioPharma.

No alerts have been found for TransCelerate BioPharma.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Getz K, et al. (2026) Insights Informing Strategies for Optimizing the Collection of Clinical Trial Data. Therapeutic innovation & regulatory science, 60(2), 563.

Staunton C, et al. (2024) Ethical framework for FACILITATE: a foundation for the return of clinical trial data to participants. Frontiers in medicine, 11, 1408600.

Blom JMC, et al. (2023) The nexus of social alliances and diverse moral domains: a bedrock for participatory clinical research. Frontiers in medicine, 10, 1250247.

Jaguste VS, et al. (2019) Risk-based monitoring: Review of the current perceptions and toward effective implementation. Perspectives in clinical research, 10(2), 57.

Hudson LD, et al. (2018) Global Standards to Expedite Learning From Medical Research Data. Clinical and translational science, 11(4), 342.

Pistollato F, et al. (2016) Alzheimer disease research in the 21st century: past and current failures, new perspectives and funding priorities. Oncotarget, 7(26), 38999.